BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Authors » Nuala Moran

Articles by Nuala Moran

Xceleron's 'Phase 0' Technology Could Speed Drug Development

Oct. 29, 2003
By Nuala Moran

Alizyme Raises £11.5M, Gets Negotiations Breathing Room

Oct. 29, 2003
By Nuala Moran
LONDON - Alizyme plc raised £11.5 million (US$19.5 million) in a placing of 6.8 million shares, giving it financial headroom as it negotiates deals for its three Phase III products, and allowing it to expand the commercial potential of its anti-obesity drug, ATL-962, by funding an additional Phase II trial in Type II diabetes. (BioWorld International)
Read More

Xceleron's 'Phase 0' Technology Could Speed Drug Development

Oct. 29, 2003
By Nuala Moran

GM Crop Trials Results Could Hurt Biotech Position In The EU

Oct. 22, 2003
By Nuala Moran
LONDON - The prospects of lifting the moratorium on genetically modified crops in Europe were undermined severely when the results of the biggest GM crop trials anywhere in the world concluded that herbicide-tolerant oil seed rape and sugar beet are more harmful to wildlife than conventional crops. (BioWorld International)
Read More

BioPartnering Europe: Will EU Follow U.S. Biotech Markets?

Oct. 22, 2003
By Nuala Moran

GM Crop Trials Results Could Hurt Biotech Position In The EU

Oct. 22, 2003
By Nuala Moran
LONDON - The prospects of lifting the moratorium on genetically modified crops in Europe were undermined severely when the results of the biggest GM crop trials anywhere in the world concluded that herbicide-tolerant oil seed rape and sugar beet are more harmful to wildlife than conventional crops. (BioWorld International)
Read More

BioPartnering Europe: Will EU Follow U.S. Biotech Markets?

Oct. 22, 2003
By Nuala Moran

Amersham Buying GE In $9.5B All-Stock Agreement

Oct. 15, 2003
By Nuala Moran
LONDON - Amersham plc, the UK's largest life sciences company, agreed to be taken over by General Electric Co. in a £5.7 billion (US$9.5 billion) deal that would create a $13 billion turnover business with a vision to drive the development of personalized medicine. (BioWorld International)
Read More

IP Firm Raises £30M In IPO; Rise In Technology Interest Hoped For

Oct. 15, 2003
By Nuala Moran

IP Firm Raises £30M In IPO; Rise In Technology Interest Hoped For

Oct. 15, 2003
By Nuala Moran
Previous 1 2 … 457 458 459 460 461 462 463 464 465 … 527 528 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing